middle.news
Noxopharm Elevates Dr Olivier Laczka to CEO to Drive Sofra Platform Expansion
9:36am on Wednesday 15th of April, 2026 AEST
•
Biotechnology
Read Story
Noxopharm Elevates Dr Olivier Laczka to CEO to Drive Sofra Platform Expansion
9:36am on Wednesday 15th of April, 2026 AEST
Key Points
Dr Olivier Laczka promoted from Chief Scientific Officer to CEO
Leadership transition aligns with Sofra™ platform advancement
Performance options granted tied to future company milestones
Sofra™ targets multi-billion-dollar autoimmune and immuno-oncology markets
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Noxopharm (ASX:NOX)
OPEN ARTICLE